XFOR missed EPS expectations by 12.04%
Mar 25, 2025, 10:35 AM
0.00%
What does XFOR do
X4 Pharmaceuticals, based in Boston, focuses on developing novel therapies for rare diseases, particularly those related to immune dysfunction. Its lead candidate, mavorixafor, targets chemokine receptor CXCR4, with additional pre-clinical candidates in development.
X4 Pharmaceuticals (XFOR) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, X4 Pharmaceuticals's actual EPS was -$0.20, missing the estimate of -$0.18 per share, resulting in a -12.04% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.